Hyperfine, Inc. (HYPR) - 10-K Summary
Business Context and Reporting Period
Company: Hyperfine, Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Hyperfine is an early-stage health technology company developing AI-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging systems. Its primary product, the Swoop® system, is designed to provide accessible, affordable brain imaging in various care settings (ICUs, emergency departments, neurology offices) where conventional MRI is inaccessible. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $13.6 million | $12.9 million |
| Gross Profit | $6.8 million | $5.9 million |
| Gross Margin | 49.8% | 45.7% |
| Net Loss | $(35.6) million | $(40.7) million |
| Operating Loss | $(37.1) million | $(43.2) million |
| Cash and Cash Equivalents (Year End) | $35.1 million | $37.6 million |
| Accumulated Deficit | $(330.0) million | $(294.4) million |
| Units Sold (Swoop®) | 38 units | 48 units |
Note: Revenue increased 5.2% year-over-year, driven by higher average selling prices, while unit volume decreased 20.8%. Net loss improved by 12.6% due to cost reduction initiatives.
Material Changes vs. Prior Period
- Revenue Growth: Total sales rose to $13.6 million from $12.9 million. Device sales increased 9.1% to $11.4 million, while service sales declined 11.3% to $2.2 million due to contract expirations and pricing adjustments.
- Cost Reductions: Operating expenses decreased 10.7% to $43.8 million. Research and Development (R&D) expenses dropped 22.4% to $17.5 million, and General and Administrative (G&A) expenses fell 7.1% to $16.3 million, primarily due to a workforce restructuring in January 2025 that reduced headcount by approximately 14%.
- Product Innovation: The company launched its next-generation Swoop® scanner powered by Optive AI™ software in mid-2025. In December 2025, it received FDA clearance for the eleventh-generation software, which includes a new multi-direction DWI sequence for improved stroke detection.
- Capital Raises: The company raised significant capital in 2025, including a $20.1 million gross proceeds underwritten public offering in October and a $6.0 million registered direct offering in February.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Commercial Expansion: Hyperfine is expanding beyond critical care into emergency departments, hospital-based clinics, and neurology offices. International expansion is underway with regulatory approvals in India (CDSCO) and CE/UKCA marks for Optive AI™ software.
- Liquidity: As of December 31, 2025, the company held $35.1 million in cash. Management expects existing resources to fund operations for at least the next 12 months. In March 2026, the company secured a $40.0 million senior secured term loan facility, with $15.0 million funded immediately.
- Profitability: The company expects to continue incurring net losses as it invests in commercialization and R&D. There is no assurance that it will achieve profitability in the future.
Key Risks:
- Going Concern: The company has a history of net losses and an accumulated deficit of $330.0 million. Continued losses and the need for additional financing pose risks to long-term viability.
- Supply Chain: Hyperfine relies on a single contract manufacturer (Benchmark Electronics) and a single-source supplier for its magnet component. Disruptions could severely impact production.
- Regulatory: Future product enhancements require FDA 510(k) clearances or PMA approvals. Failure to obtain these could hinder growth.
- Competition: The company faces competition from established medical imaging giants (GE, Siemens, Philips) and emerging portable MRI developers.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $35.1 million cash balance plus the new $40 million loan facility against projected burn rates, given the history of significant losses.
- Unit Economics: Analyze the divergence between rising revenue (driven by price) and falling unit sales (38 units in 2025 vs. 48 in 2024) to assess market adoption trends.
- Supply Chain Resilience: Confirm the status of the single-source magnet supplier and the contract manufacturer relationship, as these are critical single points of failure.
- Regulatory Milestones: Monitor the progress of the Contrast PMR study and future FDA submissions for contrast agent use, which could expand the addressable market.
- Debt Covenants: Review the terms of the March 2026 loan agreement for restrictive covenants that may limit operational flexibility.